New hope for Hard-to-Treat cancers: experimental drug SY-9453 enters human testing
NCT ID NCT07469982
First seen Mar 18, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This early-phase study tests a new drug called SY-9453 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 122 adults whose cancer has worsened after standard treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS WITH HOMOZYGOUS MTAP DELETION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.